Nothing is wrong with Dr. M
I agree. If there were, as a founder and the largest and longest term stockholder, as well as the chairman of the board, Tom Skarpelos would replace him.
So far under Dr. Missling, Anavex has been performing extremely well. The stock price will begin to more accurately reflect that after our first FDA approval, if not sooner.